Global Live Attenuated Vaccines Market - 2023-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	183 Pages	DataM Intelligence 4Market Research LLP	October, 2023	DTAM18278544

Best Price Guarantee
Price	from $4,350
Length	183 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	October, 2023
SKU	DTAM18278544

Global Live Attenuated Vaccines Market - 2023-2030

Global Live Attenuated Vaccines Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Live attenuated vaccines contains the virulence organism that is weakened . These vaccines produce immune response in the body by remaining inactive. These vaccines boost the body to produce antiboidies and memory cells in response to the specific pathogen specific to the vaccine composition.

Live attenuated vaccines are used against a variety of diseases such as influenza, chickenpox, measles, polio and tuberculosis. The advantages of live attenuated vaccines over other types of vaccines include the production of a robust, strong antibody and cell-mediated immune response, long-lasting immunity, with a relatively quick onset of action.

Market Dynamics: Drivers & Restraints

Increase in the prevalence of infectious diseases

The increase in infectious diseases has impacted the lives of a number of people. In order to prevent infections a number of new vaccines have been introduced. The increase in innovations of new vaccines has raised the growth of the market.

For instance, According to NIH, it is estimated that about 10.6 million people fell ill with TB worldwide in 2021 an increase of 4.5% from 10.1 million in 2020. Additionally, TB cases have increased from 7,874 cases in 2021 to 8,300 in 2022 in US.

Furthermore, according to CDC, it is estimated that influenza has affected 9 million people worldwide during the year 2021-2022. An increase in the burden of infectious diseases increases the demand for vaccines. Thus, an increase in the number of infectious diseases is expected to drive the market growth.

An increase in vaccine launches and an increase in newborn babies are also the driving factors of the market growth.

Restraint

Limitations associated with the vaccines

Some of the limitations of live attenuated viral vaccines include reversion to virulence, tissue damage, and others. Tissue damage due to live vaccines can lead to pathological disorders or secondary bacterial infections. Adverse reactions such as fever or rash following live, attenuated vaccines are similar to a mild form of the natural disease.

Segment Analysis

The global live attenuated vaccines market is segmented based on type, development, end-user and region.

Viral live-attenuated vaccines segment accounted for 43.1% of the market share

Viral live attenuated vaccines have been holding a dominant position in the market share over recent years. Viral live attenuated vaccines are the most widely used vaccines. They contain whole virus which is able to produce sufficient immune response without causing any disease in the host body. Viruses are weakened and are able to produce immune responses by producing memory cells in the body.

The increase in the new innovations of novel viral live attenuated vaccines is expected to hold a dominant position in the market share. On September 5, 2023, AstraZeneca introduced FLUMIST QUADRIVALENT doses in the US for the 2023-2024 influenza season. FLUMIST QUADRIVALENT is the only Food and Drug Administration (FDA)-approved needle-free, nasal-spray flu vaccine.

Additionally, on June 6, 2023, GSK plc received the US Food and Drug Administration (FDA) approval for Priorix (Measles, Mumps, and Rubella Vaccine, Live) for active immunization for the prevention of measles, mumps, and rubella (MMR) in individuals 12 months of age and older.

On May 31, 2023, Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for ABRYSVO (Respiratory Syncytial Virus Vaccine). It is the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years and older. Thus, an increase in the number of viral vaccine releases and approvals is expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to hold a significant position in the global live attenuated vaccines market share

North America holds a dominant position in the market share over recent years. The increase in infectious diseases and increase in awareness programs and campaigns in the region is expected to drive market growth in the region. The increased FDA approvals, and increase in awareness among people also drive the market growth in the region.

For instance, on September 25, 2023, the CDC launched a new flu vaccine campaign called Wild to Mild to share key information with the public about how getting a flu vaccine can reduce your risk of flu and its potentially serious outcomes.

Additionally, on November 2, 2022, the Biden Administration initiated a six-week campaign through the end of the year urging Americans to get their updated COVID-19 vaccine.

COVID-19 Impact Analysis

The COVID-19 has impacted the live-attenuated vaccines market positively. A number of research activities and, an increased number of flus during the period have increased the demand for vaccines during COVID-19. The increased production of COVID-19 vaccines using live attenuated technology has been manufactured. Thus, COVID-19 have impacted the market growth in a positive way.

Competitive Landscape

The leading companies with a significant live attenuated vaccines market share include GSK Plc, Merck KGAa, Sanofi S.A., Bio-Med Limited, Serum Institute of India Pvt Ltd., BioDiem, Polymun Scientific, AstraZeneca Plc, Takeda Pharmaceutical Company Limited., and Serum Institute of India Pvt. Ltd. among others.

Key Developments
• On December 8, 2022, Takeda received European Commission (EC) approval for marketing authorization of the company’s dengue vaccine QDENGA (Dengue Tetravalent Vaccine [Live-attenuated]) for preventing dengue disease in individuals from four years of age in the European Union (EU).
• On January 26, 2023, Bharat Biotech launched the iNCOVACC vaccine, which is an intranasal COVID-19 vaccine candidate. iNCOVACC received approval for a primary two-dose schedule and a heterologous booster dose.

Why Purchase the Report?
• To visualize the global live attenuated vaccines market segmentation based on type, development, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of live attenuated vaccines market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global live attenuated vaccines market report would provide approximately 61 tables, 56 figures, and 183 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary: 3.1. Snippet by Type; 3.2. Snippet by Development; 3.3. Snippet by End-User; 3.4. Snippet by Region
4. Dynamics: 4.1. Impacting Factors; 4.1.1. Drivers; 4.1.1.1. Increase in the prevalence of infectious diseases; 4.1.1.2. YY; 4.1.2. Restraints; 4.1.2.1. Limitations associated with the vaccines; 4.1.3. Opportunity; 4.1.4. Impact Analysis
5. Industry Analysis: 5.1. Porter's Five Force Analysis; 5.2. Supply Chain Analysis; 5.3. Pricing Analysis; 5.4. Regulatory Analysis; 5.5. Russia-Ukraine War Impact Analysis; 5.6. DMI Opinion
6. COVID-19 Analysis: 6.1. Analysis of COVID-19; 6.1.1. Scenario Before COVID; 6.1.2. Scenario During COVID; 6.1.3. Scenario Post COVID; 6.2. Pricing Dynamics Amid COVID-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During Pandemic; 6.5. Manufacturers Strategic Initiatives; 6.6. Conclusion
7. By Type: 7.1. Introduction; 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 7.1.2. Market Attractiveness Index, By Type; 7.2. Viral *; 7.2.1. Introduction; 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 7.3. Bacterial
8. By Development: 8.1. Introduction; 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development; 8.1.2. Market Attractiveness Index, By Development; 8.2. Tissue Culture *; 8.2.1. Introduction; 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 8.3. Live Animals; 8.4. Embryonated Eggs
9. By End-User: 9.1. Introduction; 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 9.1.2. Market Attractiveness Index, By End-User; 9.2. Hospitals and Clinics *; 9.2.1. Introduction; 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 9.3. Research Institutes; 9.4. Healthcare Centers; 9.5. Other
10. By Region: 10.1. Introduction; 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 10.1.2. Market Attractiveness Index, By Region; 10.2. North America; 10.2.1. Introduction; 10.2.2. Key Region-Specific Dynamics; 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development; 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.2.6.1. U.S.; 10.2.6.2. Canada; 10.2.6.3. Mexico; 10.3. Europe; 10.3.1. Introduction; 10.3.2. Key Region-Specific Dynamics; 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development; 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.3.6.1. Germany; 10.3.6.2. UK; 10.3.6.3. France; 10.3.6.4. Italy; 10.3.6.5. Spain; 10.3.6.6. Rest of Europe; 10.4. South America; 10.4.1. Introduction; 10.4.2. Key Region-Specific Dynamics; 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development; 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.4.6.1. Brazil; 10.4.6.2. Argentina; 10.4.6.3. Rest of South America; 10.5. Asia-Pacific; 10.5.1. Introduction; 10.5.2. Key Region-Specific Dynamics; 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development; 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User; 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 10.5.6.1. China; 10.5.6.2. India; 10.5.6.3. Japan; 10.5.6.4. Australia; 10.5.6.5. Rest of Asia-Pacific; 10.6. Middle East and Africa; 10.6.1. Introduction; 10.6.2. Key Region-Specific Dynamics; 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type; 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Development; 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape: 11.1. Competitive Scenario; 11.2. Market Positioning/Share Analysis; 11.3. Mergers and Acquisitions Analysis
12. Company Profiles: 12.1. GSK Plc *; 12.1.1. Company Overview; 12.1.2. Product Portfolio and Description; 12.1.3. Financial Overview; 12.1.4. Key Developments; 12.2. Merck KGAa; 12.3. Sanofi S.A.; 12.4. Bio-Med Limited; 12.5. Serum Institute of India Pvt Ltd.; 12.6. BioDiem; 12.7. Polymun Scientific; 12.8. AstraZeneca Plc; 12.9. Takeda Pharmaceutical Company Limited.; 12.10. Serum Institute of India Pvt. Ltd.; LIST NOT EXHAUSTIVE
13. Appendix: 13.1. About Us and Services; 13.2. Contact Us